Bausch Health Companies Inc (BHC) Stock Price, Quote & News

Company Profile

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company, develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, generic pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health in the United States and internationally. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segm...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 514 744 6792

Website: www.bauschhealth.com

Address:

2150 St. ElzEar Boulevard West, Laval, Canada

TopgOptions Feb. 19 at 6:42 AM

$BHC https://www.tradingview.com/chart/BHC/QK5wG7bZ-BHC-Bausch-Health-Companies-Options-Ahead-of-Earnings/

0 · Reply

WallStreetBuyDip Feb. 19 at 5:35 AM

$BHC Massive volume spike on Feb 18 with 2,780,300 shares traded compared to the average of 2,402,962. Price held steady at $6.19. Price range has been wide between $4.32 to $8.34. Waiting for a lower H% before considering an entry.

0 · Reply

SellSalix Feb. 19 at 1:57 AM

$BHC $BHC this earnings call finally proves what I’ve known for some time now; that we have here is a Leap; a long dated call option on $BLCO . If BLCO gets to $30 or more, this POS will fly, and I’m talking multi-bagger. If it doesn’t get close to $30 by then, this POS is toast! Good news is we have until 2028, but we need BLCO to perform extremely well for the next couple of years; and Xifaxan needs to remain exclusive until then. And, the bad news, we’ll have to continue to wait for while longer. Personally, I am thinking of realizing a loss on this but will continue to hold my calls.

0 · Reply

Estimize Feb. 19 at 1:33 AM

$BHC reported 1.10 EPS and 2,796 revenue for Q4. http://www.estimize.com/intro/bhc?chart=historical&metric_name=eps&utm_content=BHC&utm_med

0 · Reply

vcd103 Feb. 19 at 12:34 AM

$BHC https://ir.bauschhealth.com/~/media/Files/V/Valeant-IR/reports-and-presentations/4q-and-fy-2025-earnings-deck.pdf

0 · Reply

Sciguy67 Feb. 19 at 12:18 AM

$BHC call interest increased a 6.5?

0 · Reply

GreedyBunny Feb. 18 at 10:50 PM

$BHC CFO just basically said they will most likely separate with BLCO when the proper price is reflected by BLCO and then they will sell their equity rather than give shares to BHC holders. Finally someone said something.

1 · Reply

kbingo12 Feb. 18 at 10:49 PM

$BHC no stock distribution, sale of BLCO only option per CFO

1 · Reply

AStrokeOfLuck Feb. 18 at 10:42 PM

$BHC

0 · Reply

btradingwarehouse Feb. 18 at 10:15 PM

$BHC ...2BULLS... ... Champs !!! This all is too perfect Co. is worth $100+ share !!! ... DO NOT BUY !!! DO NOT NOT NOT SELL !!!

0 · Reply

Bausch Health Companies Inc. (BHC) Q4 2025 Earnings Call Transcript

Feb 18, 2026, 4:05 PM EST - 9 hours ago

BAUSCH HEALTH ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2025 RESULTS

Feb 17, 2026, 7:00 AM EST - 1 day ago

Bausch Health to Participate in the J.P. Morgan Global Leveraged Finance Conference

Feb 11, 2026, 8:00 AM EST - 7 days ago

Bausch Health Announces 2026 Gastrointestinal Health Scholars Program

Jan 23, 2026, 7:52 AM EST - 26 days ago

Bausch Health's brain dysfunction treatment fails late-stage trial

Jan 23, 2026, 7:45 AM EST - 26 days ago

Bausch Health Provides Update on RED-C Phase 3 Clinical Trials

Jan 21, 2026, 7:00 AM EST - 4 weeks ago

Bausch Health to Announce Fourth Quarter and Full Year 2025 Results on February 18, 2026

Jan 15, 2026, 3:15 AM EST - 4 weeks ago

Bausch Health Companies Inc. (BHC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 5, 2026, 7:00 AM EST - 6 weeks ago

Bausch Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Dec 23, 2025, 5:35 PM EST - 2 months ago

Bausch Health Announces Final Results and Expiration of Exchange Offers

Dec 8, 2025, 7:22 PM EST - 2 months ago

Bausch Health Announces Early Exchange Offer Results for Exchange Offers

Dec 2, 2025, 12:43 PM EST - 2 months ago

Bausch Health Companies Inc. (BHC) Presents at Evercore 8th Annual Healthcare Conference Transcript

Dec 1, 2025, 7:00 AM EST - 2 months ago

Bausch Health's Aesthetics Business, Solta Medical, Acquires Longtime Distribution Partner, the Shibo Group, to Strengthen Presence in China

Nov 24, 2025, 7:05 AM EST - 3 months ago

Bausch Health Announces Launch of Offers to Exchange Certain Existing Senior Secured Notes

Nov 18, 2025, 7:00 AM EST - 3 months ago

Bausch Health to Participate in the 8th Annual Evercore Healthcare Conference

Nov 13, 2025, 8:18 AM EST - 3 months ago

Bausch + Lomb CEO Brent Saunders on growth outlook: Biggest contributor will be in surgical

Nov 13, 2025, 7:00 AM EST - 3 months ago

Bausch + Lomb to Highlight Company Transformation and Growth Strategy at Investor Day

Nov 11, 2025, 7:07 AM EST - 3 months ago

Bausch Health: Solid Q3 Performance Reinforces Deleveraging Path

Nov 5, 2025, 8:00 AM EST - 3 months ago

Bausch Health's OraPharma Expands into Canada and Puerto Rico, Helping to Address Unmet Needs in Periodontal Disease

Nov 3, 2025, 4:30 PM EST - 3 months ago

Bausch + Lomb to Hold Investor Day on Nov. 13

Oct 31, 2025, 7:45 AM EDT - 3 months ago

Why Bausch Health Is A Buy After Rising 10% On Third-Quarter Results

Oct 29, 2025, 8:26 PM EDT - 4 months ago

Bausch Health Companies Inc. (BHC) Q3 2025 Earnings Call Transcript

Oct 29, 2025, 4:05 PM EDT - 4 months ago

Bausch Health Announces Third Quarter 2025 Results

Oct 20, 2025, 10:57 AM EDT - 4 months ago

Activist Investor Seeks Strategic Overhaul At Contact Lens Maker Cooper, Suggests Merger With Bausch + Lomb

Oct 9, 2025, 7:00 AM EDT - 4 months ago

Bausch Health Announces Results of Special Meeting of Shareholders

Sep 30, 2025, 8:00 AM EDT - 5 months ago

Bausch Health's Aesthetic Business, Solta Medical, Brings Non-Invasive Aesthetic Innovations to National TV

Sep 30, 2025, 7:00 AM EDT - 5 months ago

Bausch Health to Announce Third Quarter 2025 Results on October 29

Sep 29, 2025, 8:00 AM EDT - 5 months ago

Bausch Health's OraPharma Introduces "OraTalks," a New Podcast Bringing Bold Conversations to Dentistry

Sep 11, 2025, 12:04 PM EDT - 5 months ago

Bausch Health: Repricing Continues As Deleveraging Gains Traction

Sep 11, 2025, 8:35 AM EDT - 5 months ago

Bausch Health Completes Acquisition of DURECT Corporation, Expanding Late-stage Liver Disease Portfolio

Sep 11, 2025, 7:00 AM EDT - 5 months ago

Bausch + Lomb Announces Publication of enVista Envy™ Full Range of Vision Intraocular Lens Pivotal U.S. Clinical Trial

Sep 9, 2025, 7:00 AM EDT - 5 months ago

Bausch + Lomb Announces Publication of Data From a Prospective Study Evaluating the Efficacy of XIIDRA® in Alleviating Discomfort in Symptomatic Contact Lens Wearers

Sep 5, 2025, 8:02 AM EDT - 5 months ago

Bausch Health's Aesthetic Business, Solta Medical, Surpasses Milestone of 5 Million Skin Tightening Treatments with Thermage(R) Non-Surgical System

Aug 26, 2025, 8:00 AM EDT - 6 months ago

Bausch Health Announces Extension of DURECT Corporation Tender Offer to September 10, 2025

DRRX

Aug 21, 2025, 8:02 AM EDT - 6 months ago

Bausch Health, Canada Inc. Treatment for Acne Vulgaris, (Pr)CABTREO(TM) (Clindamycin Phosphate, Adapalene and Benzoyl Peroxide Gel), Now Available Through Public Drug Plans of Quebec and Saskatchewan

Aug 18, 2025, 5:48 PM EDT - 6 months ago

Bausch + Lomb board members resign after Icahn agreement ends

Aug 15, 2025, 2:30 PM EDT - 6 months ago

Bausch Health Announces Increase in Shareholding by its Chairperson of the Board and Board Changes

Aug 12, 2025, 1:02 PM EDT - 6 months ago

Why Bausch Health Stock Surged By Nearly 20%

Aug 7, 2025, 8:00 AM EDT - 6 months ago

Bausch Health Announces 2025 Gastrointestinal Health Scholars Program Winners

Jul 30, 2025, 11:30 PM EDT - 7 months ago

Bausch Health Companies Inc. (BHC) Q2 2025 Earnings Call Transcript

Jul 30, 2025, 4:05 PM EDT - 7 months ago

Bausch Health Announces Second Quarter 2025 Results

Jul 29, 2025, 2:21 PM EDT - 7 months ago

Bausch Health Adds Late-Stage Ready Alcohol Liver Disease Drug Candidate In $63 Million DURECT Buyout

DRRX

Jul 29, 2025, 7:00 AM EDT - 7 months ago

Bausch Health to Acquire DURECT Corporation, Strengthening Commitment to Developing Innovative Solutions for Patients with Liver Disease

DRRX

Jul 29, 2025, 7:00 AM EDT - 7 months ago

Bausch + Lomb Announces Publication of Phase 3 Data on LUMIFY® Preservative Free Redness Reliever Eye Drops

Jul 28, 2025, 9:10 AM EDT - 7 months ago

Bausch Health to Reduce Debt by Approximately $900 Million Using Cash On Hand

Jul 24, 2025, 8:02 AM EDT - 7 months ago

Bausch Health Announces the Appointment of Two New Members to Its Board of Directors

Jul 10, 2025, 5:00 PM EDT - 7 months ago

CORRECTING and REPLACING: Bausch Health, Canada Inc. Treatment for Acne Vulgaris, (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide gel), Now Available Through Public Drug Plans of Ontario, Nova Scotia and Two Federal Programs

Jul 10, 2025, 4:15 PM EDT - 7 months ago

Bausch Health Appoints New Chief Accounting Officer

Jul 9, 2025, 8:00 AM EDT - 8 months ago

Bausch Health, Canada Inc. Treatment for Acne Vulgaris, (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide gel), Now Available Through Public Drug Plans of Ontario, Quebec and Two Federal Programs

Jul 7, 2025, 8:00 AM EDT - 8 months ago

Bausch Health's Gastroenterology Business, Salix Pharmaceuticals, Launches Fresh "I Wish I Knew" Campaign to Educate People About Xifaxan(R) (rifaximin) for Adults at Risk of Overt Hepatic Encephalopathy Recurrence

TopgOptions Feb. 19 at 6:42 AM

$BHC https://www.tradingview.com/chart/BHC/QK5wG7bZ-BHC-Bausch-Health-Companies-Options-Ahead-of-Earnings/

0 · Reply

WallStreetBuyDip Feb. 19 at 5:35 AM

0 · Reply

SellSalix Feb. 19 at 1:57 AM

0 · Reply

Estimize Feb. 19 at 1:33 AM

$BHC reported 1.10 EPS and 2,796 revenue for Q4. http://www.estimize.com/intro/bhc?chart=historical&metric_name=eps&utm_content=BHC&utm_med

0 · Reply

vcd103 Feb. 19 at 12:34 AM

$BHC https://ir.bauschhealth.com/~/media/Files/V/Valeant-IR/reports-and-presentations/4q-and-fy-2025-earnings-deck.pdf

0 · Reply

Sciguy67 Feb. 19 at 12:18 AM

$BHC call interest increased a 6.5?

0 · Reply

GreedyBunny Feb. 18 at 10:50 PM

1 · Reply

kbingo12 Feb. 18 at 10:49 PM

$BHC no stock distribution, sale of BLCO only option per CFO

1 · Reply

AStrokeOfLuck Feb. 18 at 10:42 PM

$BHC

0 · Reply

btradingwarehouse Feb. 18 at 10:15 PM

$BHC ...2BULLS... ... Champs !!! This all is too perfect Co. is worth $100+ share !!! ... DO NOT BUY !!! DO NOT NOT NOT SELL !!!

0 · Reply

ThinkItThrough Feb. 18 at 10:11 PM

$BHC why is Tom shouting at us?

1 · Reply

gary918 Feb. 18 at 9:58 PM

$BHC algos selling on the impairment charge. Let’s see if there is any strategic plan going forward

0 · Reply

Enut Feb. 18 at 9:49 PM

$BHC will be green in the morning

0 · Reply

RazorbackAJ Feb. 18 at 9:41 PM

$BHC Overreaction in AHs - going long here with trailing stop loss at $5.50

1 · Reply

thechadrandy Feb. 18 at 9:41 PM

$BHC Garbage

0 · Reply

StocktwitsEarnings Feb. 18 at 9:36 PM

$BHC Q4 '25 Earnings Results & Recap • Reported GAAP EPS of -$0.30 • Reported revenue of $2.8B • Bausch Health projects full-year 2026 revenues from $10.63B and Adjusted EBITDA from $3.88B. Adjusted Operating Cash Flow is forecast between $1.2B and $1.28B.

0 · Reply

kbingo12 Feb. 18 at 9:25 PM

$BHC compare Tom's call to Brent's. Brent's will blow Tom away...Tom sounds scared and in over his head. Combine and eliminate Tom and underperforming team.

0 · Reply

Hshshhssos Feb. 18 at 9:13 PM

$BHC • Q4 Revenue: $2.80B (+9% reported, +6% organic) • Q4 GAAP Net Loss: -$112M • Q4 Adjusted EBITDA: $1.05B (+13%) • FY Revenue: $10.27B (+7% reported, +5% organic) • FY GAAP Net Income: $157M • FY Adjusted EBITDA: $3.54B (+7%) • 2026 Revenue Guidance: $10.625B-$10.875B • 2026 Adjusted EBITDA Guidance: $3.875B- $4.000B

0 · Reply

Angiesix Feb. 18 at 9:05 PM

$BHC Don't be so negative. JANA Partners is trying here. Let's sell a bit to retire debt, distribute 80% of $BLCO to $BHC shareholders. $COO split (Coopervision) merging with $BLCO is the ultimate goal. Each $1 bln debt retired is approx. $2.70 to $BHC share price.

1 · Reply

FU2 Feb. 18 at 8:58 PM

$BHC So at the conference, they said #'s will be at the high end of guidance. I hope these fucker-ss can deliver, or even beat on the high side.

0 · Reply

DonCorleone77 Feb. 18 at 8:48 PM

$BHC Bausch Health options imply 7.7% move in share price post-earnings Pre-earnings options volume in Bausch Health is 1.6x normal with calls leading puts 21:1. Implied volatility suggests the market is anticipating a move near 7.7%, or 48c, after results are released. Median move over the past eight quarters is 7.7%.

0 · Reply

FU2 Feb. 18 at 12:24 PM

$BHC we are never going to sell BLCO with this crappy management team. Just roll it back in and cut half of the management expenses threw terminations. No more 3 year plan crap, time to end this shit show. Over paid fucker-ssss

0 · Reply

Market Cap	2.22B
Revenue (ttm)	9.63B
Net Income (ttm)	-46.00M
EPS (ttm)	N/A
PE Ratio	1.58
Forward PE	1.47
Profit Margin	-0.48%
Debt to Equity Ratio	59.11

Volume	2,806,768
Avg Vol	2,169,196
Day's Range	N/A - N/A
Shares Out	370.90M
Stochastic %K	83%
Beta	0.42
Analysts	Hold
Price Target	$7.43